What is CagriSema, how much weight does it cause, and how does it compare to tirzepatide?

The short answer

CagriSema is a once-weekly combination of semaglutide (a GLP-1 agonist) and cagrilintide (a long-acting amylin analog), designed to stack two appetite pathways for greater weight loss than either alone. In the REDEFINE 1 trial it produced roughly 20-22% average weight loss — strong, broadly in tirzepatide's range, though the headline slightly undershot early expectations.

Evidence tier: 1–2 for the core efficacy data (REDEFINE 1 is a large phase 3 randomized trial; the phase 2 diabetes data is also randomized). Mechanism is established pharmacology. This is education, not medical advice — CagriSema is a regulated investigational/late-stage product, not a research peptide to self-source.

The key points:

• Two mechanisms in one — GLP-1 (semaglutide) plus amylin (cagrilintide), targeting appetite via different pathways
• ~20-22% average weight loss in REDEFINE 1 — in the same tier as tirzepatide
• The "miss" narrative — it slightly undershot lofty pre-trial expectations, not the same as failing
• Not a gray-market peptide — it's a late-stage pharmaceutical combination, dosed and monitored

This is a deep dive within our GLP-1 complete guide; compare it with the tirzepatide and retatrutide deep dives.

What CagriSema actually is

Evidence tier: 2 — established pharmacology.

CagriSema is Novo Nordisk's fixed-combination of two molecules in a single weekly injection: semaglutide, the GLP-1 receptor agonist already familiar from Ozempic and Wegovy, and cagrilintide, a long-acting analog of amylin. Amylin is a hormone co-secreted with insulin that promotes satiety and slows gastric emptying through a pathway distinct from GLP-1. The thesis is additive: hit appetite and energy intake through two complementary mechanisms and you get more weight loss than maxing out either one alone.

This dual-pathway logic is the same strategic idea behind tirzepatide (GLP-1 + GIP) and retatrutide (GLP-1 + GIP + glucagon), but CagriSema's second arm is amylin rather than another incretin. That makes it part of the broader "combination is the future" wave in obesity pharmacology — and it's worth being clear that this is a regulated late-stage pharmaceutical, not one of the research peptides sold in the gray market. For the structured entity summary, see our CagriSema peptide page.

The amylin angle is worth dwelling on because it's genuinely different from the incretin-stacking approach. Amylin is co-secreted with insulin from the pancreas and acts in the brainstem to promote satiety and slow gastric emptying — overlapping with GLP-1's effects but through distinct receptors and circuits. The hope is that engaging a parallel satiety system produces additive appetite suppression and may help with the weight-regain and plateau problems that limit single-mechanism drugs. Cagrilintide is engineered as a long-acting amylin analog so it can be dosed once weekly alongside semaglutide, and the two are delivered together rather than as separate shots. Whether amylin proves to be a "better" second pathway than GIP or glucagon is exactly what the maturing trial programs will sort out — for now it's a credible, mechanistically distinct third approach in the combination race.

How much weight does CagriSema cause?

Evidence tier: 1 — pivotal phase 3 trial.

In REDEFINE 1, the pivotal 68-week phase 3 obesity trial in adults without diabetes, CagriSema produced a mean weight reduction of roughly 20-22% versus placebo (Garvey 2025). That's a strong, clinically meaningful result — broadly in the same band as tirzepatide's SURMOUNT-1 and well above semaglutide's ~15% in STEP-1 (Wilding 2021). On the raw number, CagriSema is a top-tier weight-loss agent.

There's an important nuance the headlines fixated on: the result slightly undershot pre-trial expectations, which had been inflated by very strong early-phase data and analyst hype. A trial that delivers ~20% can still "disappoint" if the market priced in 25%. It's a useful lesson in reading drug news — "missed expectations" is a market verdict, not a clinical one, and a ~20% average weight loss remains excellent by any historical standard. The dosing-flexibility finding (many participants didn't reach the top dose) also colored interpretation.

How does CagriSema compare to tirzepatide and retatrutide?

Evidence tier: 1–2 — separate large trials, no head-to-head yet.

There's no direct head-to-head trial yet, so comparisons are cross-trial and should be read cautiously. On the indirect numbers, tirzepatide (SURMOUNT-1, ~20%+) and CagriSema (REDEFINE 1, ~20-22%) land in a similar band, while retatrutide has posted the highest early figures of the three in its program — see the retatrutide deep dive. Cross-trial differences in population, duration, and titration mean small gaps shouldn't be over-read.

The more meaningful distinction is mechanism and maturity. Tirzepatide is approved and has head-to-head data against semaglutide; CagriSema and retatrutide are later-stage entrants still completing their programs. For someone following this space, the honest framing is that the GLP-1 field is moving from "one drug" to "a menu of combinations," and CagriSema is a strong amylin-based entry in that menu rather than a clear winner or loser. The general class context — mechanism, access, and the rest of the pipeline — is in our GLP-1 complete guide.

What about side effects and diabetes use?

Evidence tier: 1–2 — trial data across obesity and diabetes.

CagriSema's side-effect profile is the familiar GLP-1 GI cluster — nausea, vomiting, diarrhea, constipation — most pronounced during titration and the main reason it's escalated slowly. Adding amylin doesn't escape the GI tax; if anything the appetite-suppression is part of how it works. The class cautions apply as they do across GLP-1 drugs (thyroid C-cell boxed-warning considerations, pancreatitis and gallbladder signals), and our GLP-1 side-effects guide covers the management playbook.

On the diabetes side, a phase 2 trial in type 2 diabetes showed cagrilintide plus semaglutide improved glucose control and weight versus comparators (Frias 2023), supporting the combination's metabolic credentials beyond weight alone. As with the rest of the class, the reproductive rules apply — a planned pre-conception stop with washout — which we cover in peptides to avoid in pregnancy and breastfeeding. None of this is self-experimentation territory: CagriSema is a prescribed, monitored medicine.

So is CagriSema worth paying attention to?

Evidence tier: 2–3 — synthesis.

Yes — it's a genuine top-tier weight-loss agent and one of the most important amylin-based entries in the combination era, even if the "missed expectations" narrative dented its launch story. For the reader following peptide and GLP-1 developments, the signal is that the obesity-drug landscape is fragmenting into mechanistically distinct combinations (GLP-1+GIP, GLP-1+GIP+glucagon, GLP-1+amylin), and which one suits whom will increasingly depend on tolerability, comorbidities, and access rather than a single "best" number.

The practical takeaway: don't read the analyst disappointment as clinical failure, treat cross-trial comparisons as approximate, and watch for the head-to-head and longer-term data that will actually sort these drugs out. As always, this is a regulated medicine to use under a clinician — not something to source through the channels research peptides travel.

What does CagriSema mean for the obesity-drug market?

Evidence tier: 3 — market/strategic synthesis, not clinical data.

Zooming out, CagriSema matters less as a single product and more as a signal about where obesity medicine is heading. For a decade the field was defined by single-mechanism GLP-1 drugs; now the frontier is combinations, each pairing GLP-1 with a different second pathway — GIP (tirzepatide), GIP plus glucagon (retatrutide), and amylin (CagriSema). That diversification is good for patients in the long run: different mechanisms mean different tolerability profiles, different secondary benefits, and more options when one drug doesn't suit someone or stops being accessible during a shortage.

It also reframes how to read the "CagriSema disappointed" coverage. From a patient's perspective, a ~20-22% weight-loss drug with a distinct amylin mechanism is a welcome addition to the menu regardless of whether it dethroned tirzepatide — competition tends to improve access and, eventually, price. The amylin pathway is also being explored on its own (cagrilintide as a standalone) and in other combinations, so CagriSema is best understood as one expression of a broader amylin-plus-incretin research direction rather than a one-off.

For the reader tracking this space, the practical implication is to stop thinking in terms of a single "best" weight-loss drug and start thinking in terms of fit: mechanism, side-effect tolerance, comorbidities (cardiac, diabetic, hepatic), oral-versus-injectable preference, and what's actually available where you live. CagriSema widens that menu. Whether it becomes a first-line choice will depend on real-world tolerability, pricing, and the head-to-head and long-term data still to come — but its arrival confirms that the era of combination obesity therapy is firmly underway, and that's the more durable takeaway than any single trial's headline number.

Limitations

This is educational content, not medical advice.

• No head-to-head trials yet versus tirzepatide or retatrutide — comparisons are cross-trial and approximate.
• "Missed expectations" is a market judgment, not a clinical one — ~20% weight loss is excellent historically.
• Trial averages aren't individual guarantees — response and tolerability vary.
• Class cautions apply in full — GI effects, thyroid C-cell warning, pancreatitis/gallbladder signals.
• CagriSema is a regulated pharmaceutical, not a research peptide; sourcing it outside a prescription carries real risk.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

CagriSema pairs semaglutide with the amylin analog cagrilintide to attack appetite through two pathways, and in REDEFINE 1 it delivered roughly 20-22% average weight loss — a top-tier result in tirzepatide's band, even though it undershot inflated pre-trial hype. There's no head-to-head data against tirzepatide or retatrutide yet, so treat cross-trial comparisons cautiously. The real story is the obesity field maturing into a menu of mechanistically distinct combinations, with CagriSema a strong amylin-based option — a prescribed, monitored medicine, not a gray-market peptide.

Related on this site

• GLP-1 complete guide (2026)
• Tirzepatide deep dive (2026)
• Retatrutide deep dive (2026)
• Semaglutide deep dive (2026)
• GLP-1 side effects and how to manage them
• CagriSema peptide page
• Our evidence-tier framework

References

• Garvey WT, et al. 2025. Coadministered cagrilintide and semaglutide in adults with overweight or obesity (REDEFINE 1). N Engl J Med. PMID 40544433 — pivotal phase 3 obesity trial.
• Frias JP, et al. 2023. Efficacy and safety of co-administered once-weekly cagrilintide with once-weekly semaglutide in type 2 diabetes: a phase 2 trial. Lancet. PMID 37364590 — diabetes/metabolic data.
• Wilding JPH, Batterham RL, Calanna S, et al. 2021. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 384(11):989-1002. PMID 33567185 — semaglutide-alone comparator.
• Jastreboff AM, Aronne LJ, Ahmad NN, et al. 2022. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 387(3):205-216. PMID 35658024 — cross-trial efficacy benchmark.